HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive

被引：8

作者：

Campbell, Marcia R. ^{[1
]}

Moasser, Mark M. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 13期

关键词：

GEMCITABINE; INHIBITORS; PATHWAY; ERBB3;

D O I：

10.1158/1078-0432.CCR-14-3012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting HER2 for the treatment of HER2-positive breast cancers is now a validated treatment paradigm. However, evidence suggests that this family of receptors may have important roles outside of the realm of HER2 amplification. There is considerable interest in the development of biomarkers to identify such breast cancers. (C) 2015 AACR.

引用

页码：2886 / 2888

页数：3

共 12 条

[1] ALIMANDI M, 1995, ONCOGENE, V10, P1813
[2] HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Campbell, Marcia R.
Amin, Dhara
Moasser, Mark M.
[J]. CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1373 - 1383
[3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
Cunningham, D
Humblet, Y
Siena, S
Khayat, D
Bleiberg, H
Santoro, A
Bets, D
Mueser, M
Harstrick, A
Verslype, C
Chau, I
Van Cutsem, E
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
[4] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Engelman, Jeffrey A.
Zejnullahu, Kreshnik
Mitsudomi, Tetsuya
Song, Youngchul
Hyland, Courtney
Park, Joon Oh
Lindeman, Neal
Gale, Christopher-Michael
Zhao, Xiaojun
Christensen, James
Kosaka, Takayuki
Holmes, Alison J.
Rogers, Andrew M.
Cappuzzo, Federico
Mok, Tony
Lee, Charles
Johnson, Bruce E.
Cantley, Lewis C.
Janne, Pasi A.
[J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043
[5] Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
Gordon, Vallerie
Banerji, Shantanu
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (14) : 3738 - 3744
[6] Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Jura, Natalia
Shan, Yibing
Cao, Xiaoxian
Shaw, David E.
Kuriyan, John
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (51) : 21608 - 21613
[7] Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Leary, Alexandra
Evans, Abigail
Johnston, Stephen R. D.
A'Hern, Roger
Bliss, Judith M.
Sahoo, Rashmita
Detre, Simone
Haynes, Benjamin P.
Hills, Margaret
Harper-Wynne, Catherine
Bundred, Nigel
Coombes, Gill
Smith, Ian
Dowsett, Mitch
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2932 - 2940
[8] Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Makhija, Sharmila
Amler, Lukas C.
Glenn, Dana
Ueland, Frederick R.
Gold, Michael A.
Dizon, Don S.
Paton, Virginia
Lin, Chin-Yu
Januario, Thomas
Ng, Kimmie
Strauss, Andreas
Kelsey, Stephen
Sliwkowski, Mark X.
Matulonis, Ursula
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1215 - 1223
[9] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Moore, Malcolm J.
Goldstein, David
Hamm, John
Figer, Arie
Hecht, Joel R.
Gallinger, Steven
Au, Heather J.
Murawa, Pawel
Walde, David
Wolff, Robert A.
Campos, Daniel
Lim, Robert
Ding, Keyue
Clark, Gary
Voskoglou-Nomikos, Theodora
Ptasynski, Mieke
Parulekar, Wendy
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966
[10] HER2 status and benefit from adjuvant trastuzumab in breast cancer
Paik, Soonmyung
Kim, Chungyeul
Wolmark, Norman
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13) : 1409 - 1411

← 1 2 →